Kymera Therapeutics, Inc. (KYMR), a clinical-stage biopharmaceutical company, announced the appointment of Felix J. Baker as Chairman of the Board of Directors. He succeeds Bruce Booth, who has served as Chairman of Kymera since 2016 and will remain on the Board as an Independent Director.
Baker previously served as the company's Lead Independent Director since 2024. He is also a Managing Member of Baker Brothers Investment, which he co-founded with his brother in 2000.
He also serves on the boards of BeOne Medicines AG (ONC), Bicycle Therapeutics plc (BCYC), Kodiak Sciences Inc. (KOD), and Kiniksa Pharmaceuticals International, plc (KNSA).
Kymera has traded between $36.65 and $105 over the last year.
KYMR closed Wednesday's trade at $99.87, up 1.65%. In the after hours, shares are trading up 0.33% to $100.20.
For comments and feedback contact: editorial@rttnews.com
Economic News
What parts of the world are seeing the best (and worst) economic performances lately? Click here to check out our Econ Scorecard and find out! See up-to-the-moment rankings for the best and worst performers in GDP, unemployment rate, inflation and much more.
September 04, 2026 15:08 ET The job report and foreign trade data were the main economic news from the U.S. in the first week of September. Elsewhere in North America, the Canadian central bank announced its latest policy decision. Inflation data from Eurozone was the highlight in Europe. The latest interest rate decision by the Reserve Bank of New Zealand drew attention in Asia.